醫美板塊拉昇 發改委稱支持海南高端醫美產業發展
格隆匯4月8日丨A股醫美板塊拉昇,華熙生物漲近7%,昊海生科漲5%,愛美客漲超4%,光莆股份漲超3%。發改委發佈關於支持海南自由貿易港建設放寬市場準入若干特別措施的意見提出,支持海南高端醫美產業發展。鼓勵知名美容醫療機構落户樂城先行區。海南省有關部門研究提出樂城先行區醫美產業發展需要的進口藥品、醫療器械、化粧品企業及產品清單,協助相關企業開展註冊,國家藥品監督管理部門予以支持。支持國外高水平醫療美容醫生依法依規在海南短期行醫,推動發展醫療美容旅遊產業,支持引進、組織國際性、專業化的醫美產業展會、峯會、論壇,規範醫療美容機構審批和監管。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.